-
Recent advances in non-internalized antibody-drug conjugates (ADCs).
Time of Update: 2023-01-01
2 Mechanism of action of non-internalized ADCs ADCs are typically designed to function through internalized mechanisms: after the antibody binds to the target antigen on cancer cells, the ADC is internalized by endocytosis and then degraded in lysosomes, releasing a cytotoxic payload (Figure 2A).
-
Biocytogen successfully developed the fully human nanobody mouse RenNano
Time of Update: 2023-01-01
Compared with the few other nanobody models in the world, Biocytogen's RenNano® mice carry a complete human antibody heavy-chain variable region gene with in-situ position, and the fully human single-chain antibody sequence produced can be used for drug development without in vitro humanization modification, saving a lot of time and costs, and reducing the risk of subsequent development.
-
Jacobio will present the results of the preclinical study of the combination of KRAS G12C inhibitor and SHP2 inhibitor at the ESMO ASIA 2022 meeting
Time of Update: 2023-01-01
About the summary: Topic: Treatment options in R&D : A study of the KRAS G12C inhibitor JAB-21822 as a single agent or in combination with the SHP2 inhibitor JAB-3312 in preclinical tumor models Abstract number: 30P Date: December 3, 2022 For more information, please visit the ESMO ASIA conference website: About JAB-21822 JAB-21822 is an oral small molecule KRAS G12C inhibitor independently developed by Jacobio.
-
Under the frequent acquisitions of this pharmaceutical company, it has begun to shift from buyer to seller
Time of Update: 2023-01-01
83% equity of Lyst Pharmaceutical, involving about 5 billion yuan 。 Since the beginning of this year, Fosun Pharma has also been initiating acquisitions, and on the evening of July 29, it announced that it intends to invest RMB 402.
-
This pharmaceutical company has gained a lot in the field of generic drugs! 26 product reviews have been awarded
Time of Update: 2023-01-01
【Pharmaceutical Network Enterprise News】Recently, "pharmaceutical brother" Hengrui Pharmaceutical announced that the company's levobupivacaine hydrochloride injection passed the quality and efficacy consistency evaluation of generic drugs, and the product is an amide long-acting local anesthesia and analgesic, mainly used for the treatment of surgical epidural block anesthesia.
-
Innovent will present a number of clinical data at the 2022 ESMO IO Conference and ASH Annual Meeting
Time of Update: 2023-01-01
A brief summary is as follows: European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress Conference time: December 7-9, 2022 (1) Report: Efficacy and safety of IBI110 (anti-LAG-3 monoclonal antibody) combined with sindilimab in advanced squamous non-small cell lung cancer: updated results of the Phase Ib study Report type: Poster report Poster number: 86P Principal Investigator: Prof.
-
This pharmaceutical company's APIs are accelerating to sea! The company expects annual revenue of 740 million yuan
Time of Update: 2023-01-01
Tonghe Pharmaceutical focuses on providing high-quality, high-barrier API products, the main varieties have DMF documents, and through multi-regional GMP inspection, with patented API rapid follow-up capabilities, the company actively expands the sales of products in the domestic market, forming a good pattern of synchronous sales in domestic and foreign markets 。 According to the third quarterly report of 2022, the company achieved revenue of 528 million yuan in the first three quarters, a year-on-year increase of 23.
-
Ascletis announces that its clinical trial application for the oral PD-L1 small molecule inhibitor ASC61 for the treatment of advanced solid tumors has been approved by the China National Food and Drug Administration
Time of Update: 2023-01-01
Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") today announced that ASC61, an oral small molecule inhibitor of oral PD-L1, has been approved by the National Medical Products Administration (NMPA) of China (NMPA) for a New Drug Clinical Trial (IND) application for the treatment of advanced solid tumors.
-
Mabwell published preclinical research results of CD47/PD-L1 bispecific antibody in Theranostics
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Recently, Mabwell published the preclinical results of CD47/PD-L1 bispecific antibody (6MW3211) online in the international journal Theranostics, the paper is "Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment" 。 6MW3211 is a co-light chain structure designed with differentiated affinity to ensure preferential binding to PD-L1-expressing tumor cells, and on this basis, it exerts the blocking effect of the CD47 antibody arm and activates the anti-tumor effect of T cells and Macrophage.
-
SNZ 1969 strain helps control IBS symptoms
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];The latest research shows that Sanzyme Biologics' Bacillus coagulans SNZ 1969® (a natural spore that forms probiotics) is believed to help control irritable bowel syndrome (IBS) symptoms after 50 years of use and more than 30 human studies in different age groups.
-
Bacteria "camouflage" well, see me hide from the sky
Time of Update: 2023-01-01
There are three main aspects of different decoration strategies on the surface of bacteria: (1) camouflaging bacteria, reducing their immunogenicity and pathogenicity, and improving the safety of bacterial treatment without affecting their viability and proliferation ability; (2) protect bacteria, strengthen their resistance to environmental threats, and improve bacterial bioavailability or drug availability at disease sites; (3) Endow bacteria with certain exogenous functions to effectively and accurately control the activity and biological behavior of bacteria to improve the therapeutic effect.
-
The results of KN026 second-line treatment of HER2-expressing gastric cancer or gastroesophageal junction cancer were published in the internationally renowned journal EJC
Time of Update: 2023-01-01
About KN026 KN026 is a HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights, which can bind two non-overlapping epitopes of HER2 at the same time, resulting in HER2 signal blockade, which is better than the combination of trastuzumab and pertuzumab, such as showing higher affinity, and has a potent tumor suppressor effect in HER2-positive tumor cell lines.
-
Jiachen Xihai broad-spectrum mRNA novel coronavirus seedlings were approved for phase I/II registration clinical trial by the US Food and Drug Administration
Time of Update: 2023-01-01
On November 19, 2022, Jiachen Xihai Biotechnology Co. , Ltd. (hereinafter referred to as "Jiachen Xihai"), a fast-growing innovative drug R&D biotechnology company, announced that its self-developed
-
Hanyu Pharmaceutical's HY3000 nasal spray obtained the ethical approval of the phase II clinical trial team leader
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On December 02, 2022, the phase II clinical research protocol of HY3000 nasal spray of Shenzhen Hanyu Pharmaceutical Co.
js?cdnversion='+~(-new Date()/36e5)];On December 02, 2022, the phase II clinical research protocol of HY3000 nasal spray of Shenzhen Hanyu Pharmaceutical Co.
-
Ascletis announced that the clinical trial application for ASC11, an oral 3CLpro inhibitor, has been accepted by the NMPA
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") today announced that its application for clinical trial (IND) for ASC11, an oral candidate for COVID-19 ("COVID-19") oral candidate (3CLpro), has been accepted by the National Medical Products Administration of China ("NMPA").
-
Pioneer Pharmaceutical's Phase II clinical trial in China for the treatment of female hair loss reached the primary endpoint
Time of Update: 2023-01-01
The Phase II clinical trial, led by Professor Zhang Jianzhong, Director of the Department of Dermatology, Peking University People's Hospital, is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Fredain in the treatment of adult female patients with androgenetic alopecia.
-
The blockbuster results of Zebratinib ALPINE research were published in the Journal of Clinical Oncology
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Recently, BeiGene's self-developed Bruton's tyrosine kinase (BTK) inhibitor BRUKINSA ® (zebrutinib) global phase 3 head-to-head clinical trial ALPINE study interim analysis results were published in the Journal of Clinical oncology (JCO), the international top journal, with an impact factor of 50.
-
Innovent Biologics presented Phase I clinical data for the monotherapy of solid tumors with IBI351 (KRAS G12C inhibitor) at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
Time of Update: 2023-01-01
Innovent Biopharmaceutical Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sales of innovative drugs in the field of major diseases such as on
-
Keyue Pharma announced the phase II clinical trial of KP104 for the treatment of paroxysmal nocturnal hemoglobinuria
Time of Update: 2023-01-01
On November 30, Keyue Pharmaceutical, a global biotechnology company dedicated to the development of innovative complement drugs for the treatment of immune-mediated diseases, announced on November 30 that the company has completed the first dose of KP104 in the Phase II clinical study in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
-
Ascletis announces that the clinical trial application for ASC11, a new oral drug 3CLpro inhibitor, has been approved by the US Food and Drug (FDA).
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") announced on November 23 that the U.
js?cdnversion='+~(-new Date()/36e5)];Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") announced on November 23 that the U.
js?cdnversion='+~(-new Date()/36e5)];Ascletis Pharmaceuticals Limited (HKEx: 1672, "Ascletis") announced on November 23 that the U.
